Natera, Inc. - Common Stock (NQ:NTRA)

416.48 +6.13 (+1.49%)

Delayed Quote Updated: 11:15 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

23 24 Next >

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today ↗

April 17, 2025

Via Benzinga

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗

April 17, 2025

A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Via Investor's Business Daily

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

April 15, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

April 14, 2025

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

How Do Investors Really Feel About Natera? ↗

March 11, 2025

Via Benzinga

Deep Dive Into Natera Stock: Analyst Perspectives (9 Ratings) ↗

February 28, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

February 17, 2025

Via Benzinga

Assessing Natera: Insights From 10 Financial Analysts ↗

April 10, 2025

Via Benzinga

3 Reasons NTRA Has Explosive Upside Potential

April 08, 2025

Natera currently trades at $141.03 and has been a dream stock for shareholders. It’s returned 351% since April 2020, blowing past the S&P 500’s 87.1% gain. The company has also beaten the index over...

Via StockStory

Topics Government Stocks

27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks ↗

April 07, 2025

Via The Motley Fool

Topics Artificial Intelligence

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

April 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Why NATERA INC (NASDAQ:NTRA) qualifies as a high growth stock. ↗

February 17, 2025

Should you consider NATERA INC (NASDAQ:NTRA) for high growth investing? A fundamental and technical analysis of (NASDAQ:NTRA).

Via Chartmill

Is the Market Bullish or Bearish on Natera? ↗

April 04, 2025

Via Benzinga

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

March 25, 2025

From Natera, Inc.

Via Business Wire

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

March 20, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

Via StockStory

Topics Artificial Intelligence

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings ↗

March 19, 2025

Via The Motley Fool

1 Mid-Cap Stock to Own for Decades and 2 to Brush Off

March 18, 2025

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

Why Is Natera (NTRA) Stock Soaring Today

March 11, 2025

Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, following a broad-based sell-off the previous day. The Nasdaq was down 4%, while the...

Via StockStory

Topics Stocks World Trade

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

March 10, 2025

From Natera, Inc.

Via Business Wire

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

March 04, 2025

From Natera, Inc.

Via Business Wire

Natera (NASDAQ:NTRA) Reports Bullish Q4, Guides for Strong Full-Year Sales

February 27, 2025

Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 53% year on year to $476.1 million. The company’s full-year revenue...

Via StockStory

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

From Natera, Inc.

Via Business Wire

Natera (NTRA) Q4 Earnings: What To Expect

February 26, 2025

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

February 25, 2025

From Natera, Inc.

Via Business Wire

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

February 18, 2025

From Natera, Inc.

Via Business Wire

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4 ↗

February 18, 2025

Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent...

Via Benzinga

NATERA INC is setting up nicely for a breakout. ↗

February 17, 2025

Exploring NATERA INC's Technical Signals and Breakout Potential: A technical analysis of NATERA INC (NASDAQ:NTRA) shows it may be setting up for a breakout.

Via Chartmill

The S&P 500 Fights Through Challenging Headlines To Close At New Weekly All-Time Highs ↗

February 14, 2025

In this video lesson, I review the resilient overall market, stocks on my radar for the short and long-term portfolio, and a new EOD swing trade, for Tuesday's session. Happy trading. Aloha.

Via Talk Markets

Topics Stocks Stocks / Equities

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

February 10, 2025

From Natera, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.